Focus, Forward
Our focus is on unlocking the full therapeutic potential of the NO-cGMP pathway by advancing next-generation soluble guanylate cyclase (sGC) stimulators that can address a broad range of serious and orphan diseases.
We have the expertise, team and determination to bring innovative medicines forward for patients.
Andre, Sickle Cell Disease Patient
Photo by Jermaine L. Stearns
Our Pipeline
Our current pipeline includes five differentiated sGC stimulator programs with properties tailored for the distinct serious and orphan diseases they are each intended to treat.
Discovery
DISC
IND Enabling
IND
Phase 1
PH1
Phase 2
PH2
Olinciguat
Vascular sGC Stimulator
Olinciguat
Vascular sGC Stimulator
Praliciguat
Systemic
sGC Stimulator
Praliciguat
Systemic
sGC Stimulator
IW - 6463
Central Nervous System
sGC Stimulator
IW - 6463
Central Nervous System
sGC Stimulator
Liver
Liver-targeted
sGC Stimulator
Liver
Liver-targeted
sGC Stimulator
Lung
Lung-targeted
sGC Stimulator
Lung
Lung-targeted
sGC Stimulator
Leaders in Drug Discovery and Development
We are world leaders in targeted sGC stimulator chemistry and nitric oxide-cGMP pathway pharmacology.
Our team has an exceptional track record bringing meaningful therapies to patients.
Unlocking the Full Therapeutic Potential of a Fundamental Pathway
We believe targeting the nitric oxide-cyclic cGMP pathway through sGC stimulation holds the key to addressing a broad range of severe and orphan diseases. We are working to harness the potential of this critical pathway.
How sGC Stimulation Works
Cassandra, Sickle Cell Disease Patient
With daughter Zahra and husband Markus
Spotlight on Sickle Cell Disease (SCD)
SCD is a genetic blood disorder that causes lifelong symptoms, serious complications, and decreased life expectancy.